Rare Cell Isolation for Morphological & Molecular Study

稀有细胞的形态学分离

• 批准号: 6783763
• 负责人: Jody V Vykoukal
• 金额: $ 13.71万
• 依托单位: ADEPTAS, INC.
• 依托单位国家: 美国
• 财政年份: 2004
• 资助国家: 美国
• 起止时间: 2004-08-01 至 2005-01-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6783763
• 关键词: bioengineering /biomedical engineering; biomedical equipment development; biotechnology; cell morphology; cell population study; cell sorting; clinical research; electrophoresis; human tissue; immunocytochemistry; mass spectrometry; matrix assisted laser desorption ionization; microarray technology; neoplastic cell; stainings; technology /technique development

DESCRIPTION (provided by applicant): A first step in the elucidation of the genetic changes and molecular profiles associated with the development of cancer is the isolation of rare tumor cells from a background of millions of normal cells, or the fractionation of a heterogeneous cell population into subpopulations. To this end we propose a versatile, dielectrophoresis-based cell fractionation and isolation platform that is an outgrowth of NCI IMAT funded studies currently underway at M.D. Anderson Cancer Center (MDACC). The goal of the project is to develop a device capable of separating human cells and presenting them in a familiar slide format appropriate for both cytomorphological analysis, which is still the gold standard for cancer diagnosis and staging, as well as a format that can serve as a front-end for emerging molecular analysis methods. The proposed electrosmear device utilizes a proprietary dielectrophoretic electrode array configuration and frequency scheme to levitate cells. This array is configured so that different cell types adhere to the slide in spatially distinct, characteristic bands, making the device ideal for isolating and grouping rare cells. Under an exclusive license from MDACC, Adeptas Inc. will design the appropriate electrodes and controlling electronics, design the sample chamber to permit an optional magnetophoretic separation component, assemble the device, and perform initial proof of concept tests with test particles. The biologically relevant testing of the device will be conducted at MDACC. Experiments at MDACC will utilize a variety of cultured tumor cell lines, whole blood, and buffy coat samples to demonstrate the ability of the electrosmear to isolate and trap cell subpopulations into characteristic bands based upon their dielectrophoretic properties. Key experiments will involve the isolation of tumor cells from spiked blood cell samples to test the limit of detection of the electrosmear method. The MDACC group will also test electrosmear slide compatibility with traditional cell staining methods, cytomorphological evaluation by both a pathologist and more recent automated slide counting cytometry methods, and molecular analysis methods including MALDI-TOF MS. Successful completion of this Phase I SBIR project should provide a basis for a Phase II application and commercialization of the device, which should be immediately applicable by pathologists and researchers in the life sciences.

描述（由申请人提供）：阐明与癌症发展相关的遗传变化和分子特征的第一步是，从数百万正常细胞的背景中分离了稀有肿瘤细胞，或将异质细胞群体分馏成亚种群。为此，我们提出了一个基于介电的细胞分馏和隔离平台，这是当前在M.D. Anderson癌症中心（MDACC）正在进行的NCI IMAT资助研究的生长。该项目的目的是开发能够分离人类细胞并以适合细胞形态分析的熟悉的幻灯片形式呈现的设备，这仍然是癌症诊断和分期的黄金标准，以及可以用作新兴分子分析方法的前端的格式。 所提出的电压设备利用专有的介电电动电极阵列构型和频率方案来悬浮细胞。该阵列的配置是使不同的单元格类型粘附在空间不同的特征带中的幻灯片，使该设备非常适合隔离和分组稀有细胞。根据MDACC的独家许可，Adeptas Inc.将设计适当的电极并控制电子设备，设计样品室以允许可选的磁性分离组件，组装设备并用测试粒子进行概念测试的初始证明。 该设备的生物学相关测试将在MDACC进行。 MDACC的实验将利用各种培养的肿瘤细胞系，全血和Buffy Coat样品，以证明电体基于其介电性特性的电体分离并将其捕获到特征带中的能力。关键实验将涉及从峰值血细胞样品中分离肿瘤细胞，以测试电压方法检测的极限。 MDACC组还将测试与传统的细胞染色方法，病理学家和最新的自动化幻灯片计数细胞仪方法以及包括MALDI-TOF MS在内的分子分析方法的电压载玻片兼容性。该阶段I SBIR项目的成功完成应为该设备的II期应用和商业化提供基础，这应立即由生命科学的病理学家和研究人员立即适用。

项目成果

Improved Method for Isolation of Neonatal Rat Cardiomyocytes with Increased Yield of C-Kit+ Cardiac Progenitor Cells.

改进了分离新生大鼠心肌细胞的方法，提高了 C-Kit+ 心脏祖细胞的产量。

• DOI: 10.4172/2157-7633.1000305
• 发表时间: 2015
• 期刊: Journal of stem cell research & therapy
• 作者: Rutering J;Ilmer M;Recio A;Coleman M;Vykoukal J;Alt E
• 通讯作者: Alt E